Morning Overview on MSN
The FDA just approved Auvelity for Alzheimer-related agitation — the first non-antipsychotic ever cleared for the hardest behavioral symptom families have to man…
Families caring for someone with Alzheimer’s disease now have a second FDA-cleared drug for agitation, and for the first time ...
The FDA has approved Auvelity as the first non-antipsychotic treatment for agitation in Alzheimer's disease, marking a major milestone for patients.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued ...
Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial. In the study (NCT06546995), the 71 patients from the modified analysis set ...
Findings from a phase 3 trial showed treatment with AVP-786 did not significantly improve agitation associated with dementia due to Alzheimer disease vs placebo. Otsuka Pharmaceuticals has ended the ...
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of ...
Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC score from baseline compared to placebo at 2 hours (p=0.0112) Met ...
Greetings, and welcome to the BioXcel Therapeutics. [Operator Instructions] Please note that this call is being recorded. I will now turn the conference over to our host, Vimal Mehta. Thank you. You ...
Music, light, and digital therapies show promise as safer alternatives to risky medications in easing dementia-related agitation, offering a potential path for some patients and caregivers alike.
Agitation is a common Alzheimer’s disease symptom, manifesting as pacing and restlessness as well as verbal and physical aggression to family members and caregivers. The drugs used to quell these ...
(Reuters) -BioXcel Therapeutics Inc said on Monday it will cut more than half of its workforce, as the drugmaker shifts its focus towards developing its agitation treatment for use in at-home settings ...
Agitation is a common yet unsettling symptom of Alzheimer’s disease. But there are ways to help prevent and manage it. If you care for someone with Alzheimer’s disease, you’ve likely noticed some mood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results